Stay updated with breaking news from Poster Presentation Session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
–– Late-breaking results from Phase III trial of Ocrevus subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis will be presented –– 10-year Ocrevus...
–– Late-breaking results from Phase III trial of Ocrevus (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented–– 10-year Ocrevus efficacy and safety data show significant benefit in slowing long-term disability progression and consistent lo...
/PRNewswire/ -- Amgen (NASDAQ: AMGN) will present new data from across its broad oncology innovative medicines and biosimilars portfolio and robust pipeline at...
/PRNewswire/ -- Amgen (NASDAQ: AMGN) will present new data from across its broad oncology innovative medicines and biosimilars portfolio and robust pipeline at...